Key result
A low-risk SGVI score predicted greater freedom from a composite of reinterventions or endograft complications after EVAR compared with a high-risk score (75.0% vs 66.1%; P=0.006).
Why the study?
Does the SGVI score accurately predict reinterventions and endograft complications in patients undergoing EVAR?
Cohort (n=1,207)
Yes
Does the SGVI score accurately predict reinterventions and endograft complications in patients undergoing EVAR?
Absolute Event Rate: 75% vs 66.1%
p-value: p=0.006
The SGVI morphological risk score successfully predicts mid-term reinterventions and endograft complications after EVAR, potentially enabling risk-stratified surveillance.
Supports SGVI-based stratification after EVAR; leaves open prospective validation before changing surveillance.
BACKGROUND: Lifelong surveillance is considered mandatory after endovascular repair (EVAR) of abdominal aortic aneurysms to detect endograft complications and prevent aneurysm rupture. Current protocols are not cost-effective or clinically effective. The international validity of the St George's Vascular Institute (SGVI) score for EVAR complications was examined. METHODS: The ENGAGE registry recruited patients undergoing EVAR at 79 centres in 30 countries. Reinterventions and endograft complications were recorded for up to 3 years after surgery. Preoperative aneurysm morphology was extracted from the registry database, and used to predict whether patients would be at low or high risk of complications after EVAR based on the SGVI score. Kaplan-Meier analysis was used to compare the incidence of endograft complications and reinterventions in patients predicted to be at low risk compared with those predicted to be at high risk. RESULTS: Some 1207 patients underwent EVAR, with follow-up of up to 3 years. The SGVI score accurately discriminated freedom from reinterventions (90·5 versus 79·3 per cent in low- versus high-risk patients; P < 0·001), freedom from endograft complications (77·9 versus 69·6 per cent in low- versus high-risk patients; P = 0·012), and freedom from a composite outcome measure of reinterventions or endograft complications (75·0 versus 66·1 per cent in low- versus high-risk patients; P = 0·006) during mid-term follow-up. CONCLUSION: This study has provided international validation of a morphological risk score that predicts mid-term reinterventions and endograft complications. The results may enable risk-stratified surveillance after EVAR.
No takes yet. Share an insight, caveat, or question.
Karthikesalingam et al. (2015) conducted a cohort in abdominal aortic aneurysms (n=1,207). Low risk SGVI score vs. High risk SGVI score was evaluated on freedom from a composite outcome measure of reinterventions or endograft complications (p=0.006). A low-risk SGVI score predicted greater freedom from a composite of reinterventions or endograft complications after EVAR compared with a high-risk score (75.0% vs 66.1%; P=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: